A growing number of randomized controlled trials (RCTs) have investigated the effectiveness of CKI as an add-on therapy to PBC for advanced NSCLC patients, however, the results were inconsistent and the conclusion remains unclear. This evidence concerns the gene CHKA and non-small cell lung carcinoma.